The sales launch of Zeqmelit® is the theme of AcuCort's newsletter #3, which is being published today.
The first commercial order of Zeqmelit® is the featured topic of the newsletter. Jonas Jönmark, CEO of AcuCort, discusses how the company is working to support sales efforts and prepare for the launch.
The newsletter can be read via the following link:
https://mailchi.mp/acucort/acucort-newsletter-february2024
To subscribe, register here:
https://www.acucort.se/en/#mailchimp-module
For further information:
Jonas Jönmark, CEO AcuCort AB
Tel: +46 70 3655400
Email: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.